CDK inhibitors: cell cycle arrest versus apoptosis.
Schwartz
Gary K
GK
Laboratory of New Drug Development and Gastrointestinal Cancers; Memorial Sloan-Kettering Cancer Center; 1275 York Avenue; New York, NY 10021, USA. SchwortG@mskcc.org.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis; D016203:CDC2 Protein Kinase / Q000037:antagonists & inhibitors*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects; D018797:Cell Cycle Proteins / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000378:metabolism; D005419:Flavonoids / Q000494:pharmacology; D006131:Growth Inhibitors / Q000494:pharmacology*; D006801:Humans; D000077146:Irinotecan; D010880:Piperidines / Q000494:pharmacology
D000970:Antineoplastic Agents; C493956:CDKN1A protein, human; D018797:Cell Cycle Proteins; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D005419:Flavonoids; D006131:Growth Inhibitors; D010880:Piperidines; C077990:alvocidib; D000077146:Irinotecan; D016203:CDC2 Protein Kinase; D002166:Camptothecin